Latest News and Press Releases

SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway...

Biotech and healthcare innovators are advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global ac

OCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Japan Patent Office has fully approved a Japanese patent...

REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric...

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability

Oxford, UK – March 17, 2026. Enara Bio, a pioneer in Dark Antigen® discovery and bispecific T cell engager innovation, today announced new data to be presented at the American Association for Cancer...

Myriad announces FDA approval for the MyChoice CDx Test as the Companion Diagnostic for Zejula, a PARP inhibitor from GSK, for patients with ovarian cancer

Taipei, Taiwan, March 17, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology...

- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 - - Positive Opinion from European Medicines Agency Recommending Marketing Authorization of Mavorixafor for...